Media Staff

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.

Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.

Charles Sawyers, Chair of Memorial Sloan-Kettering’s Human Oncology and Pathogenesis Program, is widely recognized as someone who is revolutionizing the molecular treatment of cancer.

Cancer patients use more blood and platelets than patients with any other illness. Memorial Sloan-Kettering is always in need of blood donations – especially during the holiday season.

Good Morning America co-host Robin Roberts recently said good-bye to her inpatient treatment team at Memorial Sloan-Kettering after undergoing a stem cell transplant to treat myelodysplastic syndrome.

A new program is training nurses across the country to identify the needs of cancer survivors and to help patients and their families achieve the best possible quality of life after treatment.